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BACKGROUND: Cervical cancer incidence in western Africa is among the highest in the world.
METHODS: To investigate human papillomavirus (HPV) infection in Guinea, we obtained cervical specimens from 831 women aged
18–64 years from the general population of the capital Conakry and from 77 locally diagnosed invasive cervical cancers (ICC).
Human papillomavirus was detected using a GP5þ/6þ PCR-based assay.
RESULTS: Among the general population, the prevalence of cervical abnormalities was 2.6% by visual inspection and 9.5% by liquid-
based cytology. Fourteen of 15 high-grade squamous intraepithelial lesions were visual inspection-negative. Human papillomavirus
prevalence was 50.8% (32.1% for high-risk types) and relatively constant across all age groups. Being single or reporting X3 sexual
partners was significantly associated with HPV positivity. HPV16 was the most common type, both among the general population
(7.3%) and, notably in ICC (48.6%). HPV45 (18.6%) and HPV18 (14.3%), the next most common types in ICC, were also more
common in ICC than in HPV-positive women with normal cytology from the general population.
CONCLUSION: The heavy burden of HPV infection and severe cervical lesions in Guinean women calls for new effective interventions.
Sixty-three per cent of cervical cancers are theoretically preventable by HPV16/18 vaccines in Guinea; perhaps more if some
cross-protection exists with HPV45.
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The Republic of Guinea in western Africa has a population of
approximately 9.4 million, of which 2 million live in the capital of
Conakry. The country shows high birth rates (5.8 children per
woman) and communicable diseases, notably malaria, which
predominate as causes of death. Estimates of cervical cancer
incidence and mortality rates in western Africa are among the
highest in the world (Ferlay et al, 2004), and in Conakry, cervical
cancer is by far the most common malignancy in women
(Koulibaly et al, 1997).
Establishing the viral aetiology of cervical cancer has raised the
hopes for primary and secondary prevention through human
papillomavirus (HPV) vaccination (Kahn and Burk, 2007) and
HPV DNA test-based screening (Cuzick et al, 2006), respectively.
The rationale and planning of such measures require population-
based epidemiological data on overall and type-specific HPV
prevalence in women with and without cancer. To this end, the
International Agency for Research on Cancer (IARC) has carried
out surveys in representative samples of women worldwide
(Clifford et al, 2005).
We report on HPV prevalence survey among a representative
sample of the general female population in Conakry, Guinea, as
well as in a corresponding sample of Guinean women with invasive
cervical cancer (ICC).
MATERIALS AND METHODS
Study methods were similar to those used for earlier IARC HPV
Prevalence Surveys (Clifford et al, 2005). In the study area of
Gbessia Port, a densely populated district of Conakry, we aimed to
enrol approximately 100 women from the general population in
each 5-year age group between 15 and 19 and 60 and 64 years. All
mentally and physically competent women, regardless of their
marital and sexual activity status, were eligible. Women were
enumerated at their homes by local community workers and
invited to the Gbessia Port Health Centre (Centre de Sante ´ de
Gbessia Port) between April and December 2006 to participate in
the study.
Of the 1725 invited women, 440 (25.5%) did not accept the
invitation, mainly because they apparently did not understand the
need for gynaecological examination in the absence of symptoms.
Acceptance was similar in all the age groups, but owing to the age
structure of the population, relatively few women over 44 years of
age could be invited (life expectancy of women in Guinea was
estimated in 2004 to be 55 years [www.who.int]). In addition,
among the 462 women below age 25 years who accepted the
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yinvitation to the study clinic, 213 (of whom 148 were self-declared
virgins) were unwilling to undergo a pelvic examination, and opted
to provide only a blood sample. Hence, no cervical cell specimen
was collected for these 213 women; an additional 73 women aged
25 years or older did not undergo a pelvic examination mainly
because of heavy menstrual bleeding.
A structured questionnaire was administered by one of the five
nurses in the local dialect covering socio-demographic character-
istics, reproductive and menstrual factors, sexual habits, including
those of the participants and their husbands’ and lifetime use of
contraceptive methods.
A total of 999 women underwent a pelvic examination by one of
the three midwives. Three women presented with an advanced
cervical cancer that did not allow for collection of an adequate
cervical cell sample. Among the remaining 996, a sample of
exfoliated cervical cells for liquid-based cytology and HPV testing
was collected. A cytobrush, after insertion into the endocervical
canal, was rotated gently at 1801 to collect cells, was then placed
with its cellular material in a vial containing PreservCyt media
(Cytyc-Hologic, Marlborough, MA, USA). The cervix was then
inspected with acetic acid (VIA) and visual inspection with Lugol’s
iodine (VILI), with results reported according to the IARC criteria
(Sankaranarayanan and Wesley, 2003).
Slides for liquid-based cytology were prepared using a Thin Prep
3000 processor (Cytyc-Hologic), stained according to manufac-
turer’s instructions and read at the Department of Pathology at the
Vrije University Medical Center, Amsterdam, the Netherlands.
Cytological diagnosis was formulated according to CISOE-A
standards and was translated into the Bethesda 2001 terminology
system (Bulk et al, 2004). Confirmatory biopsies, when available,
were read (MK) in the Centre National d’Anatomie Pathologique,
Centre Hospitalier Universitaire (CHU) de Donka.
Women presenting with ICC at the gynaecological clinic of the
CHU de Donka, Conakry, were identified between January 2006
and March 2007. The collection of a tumour biopsy for study
purposes was possible for all 99 women diagnosed with ICC; most
were classified as stage II (51 women) or III (44 women). Biopsies
were fixed with buffered formalin, embedded in paraffin (MH),
then read (MK) in the Centre National d’Anatomie Pathologique,
CHU de Donka. HIV testing was available for 41 women with ICC,
of which eight (19.5%) were HIV-positive; among 19 women with
ICC below age 45 years, six were HIV-positive.
All participants, whether from the HPV prevalence survey or
those with ICC, signed informed consent forms according to the
recommendations of the IARC and the CHU de Donka ethical
review committees, both of which approved the study.
HPV testing was performed on exfoliated cervical cells and ICC
biopsies in the Department of Pathology at the Vrije University
Medical Center. DNA was extracted from the PreservCyt sample
using magnetic beads (Macheri-Nagel, Du ¨ren, Germany) on a
robotic system (Hamilton, Germany), according to the manufac-
turer’s instructions. Invasive cervical cancer biopsies were
sectioned using a ‘sandwich’ approach, whereby inner tumour
sections were destined for HPV testing and outer sections for
histological confirmation of tumour tissue. One or more five lM
sections representing approximately 1cm
2 of tissue were pre-
digested with Proteinase K after which DNA was extracted using
magnetic beads (Macheri-Nagel, Germany).
Beta-globin PCR analysis was performed first to confirm the
presence of human DNA in all specimens (Roda Husman et al,
1995). The overall presence of HPV DNA was determined by
performing a general primer GP5þ/6þ-mediated PCR, which
permits the detection of a broad spectrum of genital HPV types at
the subpicogram level (Jacobs et al, 2000). Human papillomavirus
positivity was assessed by hybridisation of PCR products in an
enzyme immunoassay using two HPV oligoprobe cocktails that,
together, detect the following 44 HPV types: HPV6, 11, 16, 18, 26,
30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57,
58, 59, 61, 64, 66, 67, 68, 69, 70, 71 (equivalent to CP8061), 72, 73,
81 (equivalent to CP8304), 82 (IS39 and MM4 subtypes), 83
(equivalent to MM7), 84 (equivalent to MM8), cand85, 86, cand89
(equivalent to CP6108) and JC9710. Subsequent HPV typing was
performed by reverse line blot hybridisation of PCR products, as
described earlier (van den Brule et al, 2002). In this typing format,
all aforementioned HPV types were individually genotyped, except
for the uncommon HPV types 32, 83, 84, 85, 86 and JC9710.
Oligoprobes representing the latter types were loaded as a pool on
the reverse line blots and consequently were genotyped as a pool.
Human papillomavirus types considered high risk for this analysis
that comprised HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68,
73 and 82 (Mun ˜oz et al, 2003); all other HPV types were considered
low risk.
Statistical analysis
Odds ratios (ORs) for HPV positivity and corresponding 95%
confidence intervals (CIs) were calculated by means of uncondi-
tional logistic regression equations, adjusted for age group (15–24,
25–34, 35–44, 45–54, 55–64 years), marital status (never- or ever-
married) and lifetime number of sexual partners (1, 2 and X3), as
appropriate. The statistical significance of trends for ORs was
assessed by considering the categorical variable as a continuous
variable in the logistic model. Prevalence ratios and corresponding
95% CIs were used to compare the relative frequency of the most
common HPV types in HPV-positive women with ICC with that
among cytologically normal HPV-positive women from the HPV
prevalence survey.
RESULTS
Of 996 women who provided cervical cell samples, 84 had
inadequate HPV DNA results (77 b-globin-negative, seven miss-
ing), and an additional 81 had inadequate cytology, leaving 831
women with valid results for both HPV and cytology. Among
them, 79 (9.5%) had abnormal cytological findings, including 48
(5.8%) atypical squamous cells of undetermined significance
(ASCUS), 16 (1.9%) low-grade squamous intraepithelial lesions
(LSIL) and 15 (1.8%) HSIL.
Overall HPV prevalence was 50.8% (78.5% and 47.9% among
women with and without cervical abnormalities, respectively,
Table 1). The corresponding age-standardised prevalence to the
world population was 51.5% (95% CI: 48.0–55.0). In total, 275
(33.1%) women had single-type and 147 (17.7%) had multiple-type
infections. Prevalence of high-risk and low-risk types (32.1, 30.5%,
respectively) was similar. The commonest high-risk types with
normal cytology were HPV16 (6.7%), 45 (4.7%), 52 (4.0%), and 18,
35 and 58 (3.2% each). HPV66, 42 and 81 were the most commonly
detected low-risk types. HPV16 was also the commonest type
(13.9%) among women with cervical abnormalities, of whom
59.5% had high-risk types. The prevalence of high-risk HPV types
in women with HSIL or worse was 73.3% (data not shown).
Twenty-one women had abnormalities suspected at VIA/VILI.
The correlation between the results of VIA/VILI and those of
liquid-based cytology and HPV testing was poor (Table 2). VIA/
VILI identified one HSIL (that was shown to be ICC by histology),
but missed 14 of 15 HSIL, 15 of 16 LSIL and all 48 ASCUS. The
proportion of suspected abnormalities at VIA/VILI did not differ
significantly between high-risk HPV-positive (7/264; 2.7%) and
high-risk HPV-negative (14/558; 2.5%) women (w
2
1¼0.0146,
P¼0.904).
Of the 21 women with suspected abnormalities at VIA/VILI, 17
accepted referral to colposcopy and 10 had colposcopy-directed
biopsies, none of which showed lesions except the aforementioned
ICC. Repeated attempts were also made after cytological findings
became available (i.e., approximately one year and a half after the
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detected at VIA/VILI but HSIL found at liquid-based cytology.
Three women, however, had moved far from Conakry, one was not
found at her address, one had died of a disease other than cervical
cancer and one was in the third trimester of pregnancy. Of the
eight biopsies taken, one was inadequate, three showed cervical
intraepithelial neoplasia 1 and the other four showed no cervical
lesion.
Figure 1A and B show, respectively, the prevalence of HPV (any
HPV type, HPV16 and/or 18 and any high-risk types and low-risk
types, separately) and of VIA/VILI and cytological abnormalities
by age group. Human papillomavirus prevalence was 56.1% among
women younger than 25 years, and dropped to 45.3% in women
aged 35–44 years, before increasing again up to 55% in women
aged 45 years or older. Age-specific patterns were similar for the
prevalence of HPV16 and/or 18 and any high-risk type. When 157
women who had never been married (75.8% of whom were o25
years) were excluded, HPV prevalence below age 25 years
decreased to 46.3% (Figure 1A). VIA/VILI and cytological
abnormalities increased up to age 35–44 years and then declined.
Table 3 shows the relationship between HPV positivity and
various characteristics of participants according to two different
models. In the age-adjusted model, significant differences in HPV
positivity were observed by age group (OR for 35–44 vs o25
years¼0.65; 95% CI: 0.44–0.95), marital status (OR in single vs
married women¼1.60; 95% CI: 1.04–2.45) and number of lifetime
sexual partners (OR for X3 vs 1 partner¼1.71; 95% CI: 1.03–
2.84). These three associations were slightly attenuated in the
Table 1 Prevalence of HPV types by cytological findings and overall among 831 women (Conakry, Guinea, 2006–2008)
Normal cytology (N¼752) Abnormal cytology (N¼79) Total (N¼831)
HPV type Single Multiple Total (%) Single Multiple Total (%) Single Multiple Total (%)
HPV  — — 392 (52.1) — — 17 (21.5)
a — — 409 (49.2)
HPV+ 241 119 360 (47.9) 34 28 62 (78.5) 275 147 422 (50.8)
High-risk HPV+ 118 102 220 (29.3) 23 24 47 (59.5) 141 126 267 (32.1)
Low-risk HPV+ 123 96 219 (29.1) 11 23 34 (43.0) 134 119 253 (30.5)
High-risk infections
16 24 26 50 (6.7) 7
b 4
b 11 (13.9) 31 30 61 (7.3)
18 13 11 24 (3.2) 1 2
b 3 (3.8) 14 13 27 (3.3)
31 5 5 10 (1.3) 2 3
b 5 (6.3) 7 8 15 (1.8)
33 11 11 22 (2.9) 4
b 5
a 9 (11.4) 15 16 31 (3.7)
35 9 15 24 (3.2) 2 2 4 (5.1) 11 17 28 (3.4)
39 4 3 7 (0.9) 0 0 0 4 3 7 (0.8)
45 11 24 35 (4.7) 4
a 1 5 (6.3) 15 25 40 (4.8)
51 5 9 14 (1.9) 0 2
b 2 (2.5) 5 11 16 (1.9)
52 7 23 30 (4.0) 1 6
b 7 (8.9) 8 29 37 (4.5)
56 8 8 16 (2.1) 0 2 2 (2.5) 8 10 18 (2.2)
58 8 16 24 (3.2) 1
b 3
b 4 (5.1) 9 19 28 (3.4)
59 3 3 6 (0.8) 0 0 0 3 3 6 (0.7)
68 4 3 7 (0.9) 0 1 1 (1.3) 4 4 8 (1.0)
73 3 5 8 (1.1) 0 4 4 (5.1) 3 9 12 (1.4)
82 3 3 6 (0.8) 1 1 2 (2.5) 4 4 8 (1.0)
Subtotal 118 165 283 — 23 36 59 — 141 201 342 —
Low-risk infections
6 2 7 9 (1.2) 0 2 2 (2.5) 2 9 11 (1.3)
11 2 1 3 (0.4) 0 0 0 2 1 3 (0.4)
26 2 2 4 (0.5) 0 0 0 2 2 4 (0.5)
30 4 4 8 (1.1) 1 0 1 (1.3) 5 4 9 (1.1)
34 0 1 1 (0.1) 0 0 0 0 1 1 (0.1)
40 0 3 3 (0.4) 0 1 1 (1.3) 0 4 4 (0.5)
42 11 9 20 (2.7) 0 4
b 4 (5.1) 11 13 24 (2.9)
43 2 10 12 (1.6) 0 1 1 (1.3) 2 11 13 (1.6)
44 0 0 0 0 1
b 1 (1.3) 0 1 1 (0.1)
53 1 5 6 (0.8) 1 1 2 (2.5) 2 6 8 (1.0)
54 0 4 4 (0.5) 0 1 1 (1.3) 0 5 5 (0.6)
55 0 5 5 (0.7) 0 2 2 (2.5) 0 7 7 (0.8)
61 0 1 1 (0.1) 0 0 0 0 1 1 (0.1)
64 1 0 1 (0.1) 0 0 0 1 0 1 (0.1)
66 7 19 26 (3.5) 3
b 5
b 8 (10.1) 10 24 34 (4.1)
67 5 12 17 (2.3) 0 3 3 (3.8) 5 15 20 (2.4)
69 6 9 15 (2.0) 0 1 1 (1.3) 6 10 16 (1.9)
70 2 5 7 (0.9) 1 2 3 (3.8) 3 7 10 (1.2)
72 8 10 18 (2.4) 0 0 0 8 10 18 (2.2)
81 15 8 23 (3.1) 0 0 0 15 8 23 (2.8)
CP6108 3 3 6 (0.8) 0 0 0 3 3 6 (0.7)
Low-risk cocktail
c 22 32 54 (7.2) 2 11
a 13 (16.5) 24 43 67 (8.1)
Subtotal 93 150 243 — 8 35 43 — 101 185 286 —
X 30 0 30 (4.0) 3
b 0 3 (3.8) 33 0 33 (4.0)
Total infections 241 315 556 — 34 71 105 — 275 386 661 —
aIncludes two HSIL.
bIncludes one HSIL.
cIncludes HPV32,83,84,85,86,JC9710. HPV¼human papillomavirus; HSIL¼high-grade squamous intraepithelial lesions; N¼number;
X¼uncharacterised type.
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sexual partners.
Education, number of births, age at first sexual intercourse,
husbands’ polygamy or extra-marital sexual relationships and
lifetime use of hormonal contraceptives were unrelated to HPV
positivity in either adjustment model (Table 3) as were smoking
habits, condom use (reported by only 16 women) and history of
spontaneous or induced abortions (data not shown). Only six
(0.7%) participants reported having had previous cervical cancer
screening.
Beta-globin-negative ICC biopsies (22) were excluded; among
the remaining 77 ICC biopsies with valid HPV results, 8 were
adeno- and the rest were squamous-cell carcinoma. The median
age of women with ICC was 45 years (range: 23–80 years). Seven
ICC biopsies, including one adenocarcinoma, were HPV-negative.
Type-specific HPV prevalence in 70 HPV-positive ICC and 360
cytologically normal HPV-positive women from the HPV pre-
valence survey are compared in Table 4. HPV16 was found in 34
(48.6; 95% CI: 36.4–60.8%) HPV-positive ICC biopsies. The next
commonest types were HPV45 (18.6; 95% CI: 10.3–29.7%) and 18
(14.3; 95% CI: 7.1–24.7%). Prevalence ratios in women with ICC vs
cytologically normal women were 3.5 (95% CI: 2.2–5.5) for
HPV16, 2.1 (95% CI: 0.9–4.6) for HPV18; 1.9 (95% CI: 0.9–3.7) for
HPV45 and 0.8 (95% CI: 0.5–1.2) for high-risk types other than 16
or 18. Multiple-type infections were much less common in HPV-
positive women with ICC than in HPV-positive women with
normal cytology (Table 4). Among the five ICC biopsies deriving
from HIV-infected women with a valid HPV result, HPV16, 45, 18
were found in two, two and one woman, respectively.
DISCUSSION
Our large study, the first on HPV infection in Guinea, showed a
very high (50.8%) prevalence of HPV, and nearly no history of
cervical cancer screening. Approximately one-third of women in
our survey were infected with high-risk HPV types and four
prevalent ICC were discovered.
The age-standardised HPV prevalence we found in Conakry
(51.5%) was considerably higher than that observed in earlier
studies performed using the same HPV testing protocol
in areas at high risk for cervical cancer such as South America
(12–18%) and India (17%) or even another western African popu-
lation in Nigeria (27%) (Franceschi et al, 2006). It is also of the
highest HPV prevalence reported in any study in western Africa
(Xi et al, 2003; Wall et al, 2005; Lack et al, 2005) or other parts of
sub-Saharan Africa (de Sanjose ´ et al, 2007; Castellsague ´ et al,
2008), with the exception of those that included only, or a majority
of, HIV-positive women (Sahasrabuddhe et al, 2007). Differences
in age and sensitivity of PCR testing methods, however, limit the
direct comparability with studies other than the IARC HPV
Prevalence Surveys.
Nearly half of study women reported having two sexual partners
or more in their lifetime, and over two-thirds reported husband’s
Table 2 Cytological abnormalities and detection of high-risk HPV types by presence of suspected abnormalities at VIA/VILI among 822 women
a
(Conakry, Guinea, 2006–2008)
VIA/VILI
Normal Abnormal
Cytology High-risk HPV  High-risk HPV+ All High-risk HPV  High-risk HPV+ All
Normal 513 211 724 13 6 19
ASCUS 24 24 48 0 0 0
LSIL 4 11 15 0 1 1
HSIL 3
b 11 14 1
c 01
All 544 257 801 14 7 21
aNine women without VIA/VILI results were excluded.
bIncluding one positive for HPV66.
cPositive for HPVX. ASCUS¼atypical squamous cells of undetermined significance;
HPV¼human papillomavirus; HSIL¼high-grade squamous intraepithelial lesions; LSIL¼low-grade squamous intraepithelial lesions; VIA/VILI¼visual inspection with acetic acid
or Lugol’s iodine.
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Figure 1 Age-specific prevalence of (A) HPV DNA by HPV type(s) overall (831 women) and among married women only (674 women) (B) cervical
abnormalities at VIA/VILI and liquid-based cytology. Conakry, Guinea, 2006–2008. ASCUS, atypical squamous cells of undetermined significance; HPV,
human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; VIA, visual inspection with acetic acid;
VILI, visual inspection with Lugol’s iodine.
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high-risk sexual behaviour can help to explain the elevated HPV
prevalence in this study. Conversely, on account of the very high
frequency of HPV infection that emerged in our study, it is not
surprising that HPV-negative and -positive women did not differ
by various characteristics, including education level, except for a
moderately increased infection risk in single women and women
who reported three sexual partners or more in their lifetime.
An influence of undetected HIV infection on high HPV
prevalence in our study women cannot be ruled out, as the
protocol of the IARC HPV Prevalence Surveys does not include
HIV testing. In 2004, a survey of pregnant women estimated the
prevalence of HIV to be 4.2% nationally, and 6% in Gbessia Port,
Conakry; this seemed to be fairly uniform across age groups,
implying a well-established epidemic, but was somewhat higher
among unmarried women (9.2%) (Ministe `re de la Sante ´ Publique,
2005). HIV infection among tested women with ICC (20%) was
high considering the limited life expectancy of people with HIV/
AIDS during the study period (Franceschi and Jaffe, 2007).
One of the main aims of the IARC HPV Prevalence Surveys
concerns the variations of age-specific and type-specific HPV
prevalence by geographical region. The age-specific curve of HPV
prevalence in Guinea resembled the age curves reported earlier in
Nigeria (Thomas et al, 2004), India (Franceschi et al, 2005) and
China (Dai et al, 2006; Li et al, 2006; Wu et al, 2007), but differed
from the steep decrease in prevalence seen by age in high-resource
countries (Franceschi et al, 2006; De Vuyst et al, 2009). A modest
peak in women below age 25 years in Guinea was accounted for by
Table 3 ORs for HPV positivity and corresponding 95% CIs according to selected characteristics among 831 women (Conakry, Guinea, 2006–2008)
HPV-positive
Characteristics
a N women N (%) OR
b 95% CI OR
c 95% CI
Age group (years)
o25 214 120 (56.1) 1 1
25–34 212 100 (47.2) 0.70 (0.48–1.02) 0.78 (0.51–1.21)
35–44 212 96 (45.3) 0.65 (0.44–0.95) 0.70 (0.44–1.12)
45–54 123 70 (56.9) 1.03 (0.66–1.62) 1.19 (0.71–2.00)
55–64 70 36 (51.4) 0.83 (0.48–1.42) 1.00 (0.54–1.84)
w
2
1 for trend 0.13; P¼0.716 0.51 P¼0.473
Education
None 411 209 (50.9) 1 1
Primary 176 86 (48.9) 0.93 (0.65–1.34) 0.91 (0.63–1.32)
Secondary or higher 244 127 (52.1) 1.03 (0.74–1.43) 0.94 (0.66–1.32)
Marital status
Married 586 285 (48.6) 1 1
Single 157 95 (60.5) 1.60 (1.04–2.45) 1.55 (1.00–2.41)
Widowed/divorced
d 88 42 (47.7) 0.89 (0.55–1.43) 0.88 (0.54–1.42)
Number of births
0 170 85 (50.0) 1 1
1–2 226 122 (54.0) 1.32 (0.87–2.00) 1.45 (0.93–2.27)
3–5 225 103 (45.8) 1.06 (0.66–1.69) 1.32 (0.79–2.19)
X6 208 111 (53.4) 1.31 (0.77–2.26) 1.64 (0.93–2.90)
w
2
1 for trend 0.42; P¼0.518 2.11 P¼0.146
Age at 1st intercourse (years)
X18 216 112 (51.9) 1 1
16–17 455 231 (50.8) 0.92 (0.66–1.27) 0.90 (0.64–1.25)
r 15 133 64 (48.1) 0.78 (0.50–1.21) 0.78 (0.50–1.22)
w
2
1 for trend 1.12; P¼0.290 1.29 P¼0.256
Lifetime sexual partners
1 454 227 (50.0) 1 1
2 273 136 (49.8) 1.08 (0.78–1.48) 1.06 (0.77–1.46)
43 76 46 (60.5) 1.71 (1.03–2.84) 1.64 (0.98–2.72)
w
2
1 for trend 3.23; P¼0.072 3.07 P¼0.080
Polygamous husband
No 196 93 (47.5) 1 1
Yes 621 323 (52.0) 1.31 (0.93–1.84) 1.30 (0.91–1.86)
Husband’s extra-marital sexual relationships
No 103 52 (50.5) 1 1
Yes 701 357 (50.9) 1.11 (0.72–1.72) 1.10 (0.70–1.72)
Use of hormonal contraceptive
Never 740 371 (50.1) 1 1
Ever 90 50 (55.6) 1.30 (0.84–2.04) 1.15 (0.72–1.83)
aSome figures do not add up to the total because of a few missing values.
bAdjusted for age group, as appropriate.
cAdjusted for age group, ever/never married and lifetime
number of sexual partners (1,2,42), as appropriate.
dIncluding nine divorced women. CI¼confidence intervals; HPV¼human papillomavirus; N¼number; OR¼odds ratios.
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(Franceschi et al, 2006). By contrast, in IARC HPV Prevalence
Surveys in India and China it was considered socially unacceptable
to invite unmarried women (Franceschi et al, 2005; Dai et al, 2006;
Li et al, 2006; Wu et al, 2007). In some earlier studies from sub-
Saharan Africa, HPV prevalence also remained high (Kuhn et al,
2000; Thomas et al, 2004; Wall et al, 2005) or even increased
(Xi et al, 2003) in middle and old age, whereas peaks in young
women were reported by other investigators (Serwadda et al, 1999;
Womack et al, 2000; Castellsague ´ et al, 2001; De Vuyst et al, 2003;
Baay et al, 2004).
With respect to the relative importance of different HPV types,
HPV16 was the commonest type overall, that is, 13.9%, 17.7% and
48.6%, respectively, in cytologically normal and abnormal women
and in women with ICC (Clifford et al, 2005; Smith et al, 2007).
Noticeably, however, the high proportion of HPV45 (18.6; 95% CI:
10.3–29.7%) is consistent with a meta-analysis of HPV type
distribution in ICC from western Africa (Smith et al, 2007).
Elsewhere, HPV45, a high-risk type that, similar to HPV18, belongs
to the a-7 species, is usually less frequently detected than HPV18 in
cytologically normal women (de Sanjose ´ et al, 2007) and women
with ICC (Smith et al, 2007).
On account of the lack of experienced cytologists and HPV
testing in Conakry, we relied on VIA/VILI for the immediate
clinical management of study women from the HPV prevalence
survey. Despite the substantial experience of study midwives
in visual inspection (Sankaranarayanan et al, 2004), the majority
(77/79) of cytological abnormalities later showed by liquid-based
cytology were VIA/VILI-negative (including 14/15 HSIL), and
61.9% of abnormalities suspected at VIA/VILI were found in
cytologically normal women who were negative for high-risk HPV
types. None of the 10 biopsies taken among VIA/VILI-positive
women, with the exception of one ICC case, showed cervical
intraepithelial neoplasia of any grade.
Major strengths of our study include the large number of
women, high participation, reliance on high-quality HPV testing
and liquid-based cytology, and presence of a concurrent series of
women with ICC drawn from the same study area. Limitations
include the lack of information on HIV status and the relatively
high proportion of b-globin-negative samples in the HPV
prevalence survey, and of HPV-negative findings in paraffin-
embedded ICC biopsies. Most important, the lack of prompt
histological confirmation of abnormalities and of random biopsies
did not allow us to accurately estimate sensitivity and specificity of
different methods. A prolonged curfew in 2007 delayed not only
the shipment of cervical cell samples to Europe and, hence, the
availability of cytological and HPV findings, but also the recall of
women. Substantial population mobility and scarcity of pathology
staff in Conakry also hampered the appropriate work up of
screening positive women.
The very heavy burden of HPV infection and severe cervical
lesions in Guinea calls for new effective interventions. The quality
of VIA/VILI should be greatly improved, or other types of
screening used (e.g., rapid HPV test, Qiao et al, 2008), whereas
screen-and-treat approaches should be encouraged for recalling
women. With respect to the potential benefit of vaccination, the
fraction of ICC preventable in Guinea (62.9; 95% CI: 50.5–74.1) by
a vaccine including HPV16/18, is compatible with the worldwide
estimate (Smith et al, 2007), but would be substantially improved if
some cross-protection between HPV16/18 and HPV45 was
confirmed to exist (Barr and Sings, 2008; Jenkins, 2008).
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